

Drug Monograph

Drug Name: **Hexatrione® (triamcinolone) ampule**
 Drug Class: **Analgesics: Synthetic Glucocorticoids**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Hexatrione is now available as an unapproved drug for use during a drug shortage (Aristospan®), in a 40 mg/2 ml ampule.

Manufacturer: Distributed by: Medexus Pharma, Inc., Chicago, IL 60606.

Indications: Hexatrione is indicated for the intra-articular or soft tissue administration of Hexatrione 2% in the following rheumatological conditions: inflammatory arthritis (adult forms, juvenile idiopathic arthritis in infants ≥1 year, in children, and in adolescents) and arthritis in flare.

Costs: \$65 per 2 ml ampule containing 40 mg/2 ml solution for injection. *Wholesale Acquisition Cost*

Summary of Findings: MO HealthNet Division recommends Open Access status for this product.

Status Recommendation:

<input type="checkbox"/> Clinical Edit	<input type="checkbox"/> PA Required
<input checked="" type="checkbox"/> Open Access	<input type="checkbox"/> PDL

Type of PA Criteria:

<input type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Non-Preferred
<input checked="" type="checkbox"/> No PA Required	<input type="checkbox"/> Preferred

Prepared by: April Ash, PharmD
 Date: September 2, 2021